According to a new review, eating mushrooms may lower your risk of developing stomach cancer, and the benefits may be due to the fungi’s useful characteristics. To determine the connection between mushroom consumption and gastric cancer risk, the review examined the findings of a meta-analysis of previously published studies and the Stomach Cancer Pooling (StoP) Project. It was discovered that “higher mushroom consumption was associated with a lower risk of gastric cancer.” Eleven studies totaling 3,900 cases of stomach cancer and 7,792 control cases made up the StoP Project. Through questionnaires about food consumption, the mushrooms of study participants were assessed. Participants who consumed the most mushrooms compared to those who ate the fewest mushrooms had a relative risk (RR) of gastric cancer of 0.82. The researchers present a plausable analysis, but more research is needed to confirm if eating mushrooms truly reduces gastric cancer risks and, if so, why.

As reported at the at the AACR Annual Meeting 2023, the combination of Ianalumab and ibrutinib showed promising results in treating chronic lymphocytic leukemia (CLL) in a phase 1b, dose-escalation and expansion trial. Ianalumab, an anti-BAFF-R monoclonal antibody, works by inhibiting B-cell differentiation, proliferation, and survival, and depleting B-cells through antibody-dependent cellular cytotoxicity within the tumor microenvironment. The trial treated 15 patients with CLL who were already receiving ibrutinib with different doses of Ianalumab for 6 cycles, with patients continuing the combination up to cycle 8 if they showed evidence of disease, and then followed up every 3 months for 2 years. The ORR at cycle 9 or before treatment discontinuation was 56.7%, with a complete response (CR) rate of 37.8%. Patients who were in their first line of treatment showed better outcomes than patients who had relapsed or refractory disease, with the ORR for previously-untreated patients being 81.8% with a CR of 54.5% and a CR + CRi of 63.6%. Additionally, 45.9% of patients achieved undetectable minimal residual disease (uMRD) in blood or bone marrow by cycle 9 of treatment, including 63.6% of patients in their first line of therapy and 38.5% of patients with relapsed/refractory disease. There were […]

An essential component of successfully enhancing transplant outcomes is early viral infection prevention. Clinically severe viral infections have been successfully avoided in hematopoietic cell transplant patients with prophylactic and preventive therapy with antiviral medications. Through a better understanding of the biology and risk factors, the introduction of novel antiviral agents, and developments in immunotherapy, significant progress has been made in the past few decades in preventing viral infections. There is solid proof that herpes simplex virus, varicella-zoster virus, and CMV infection and illness can be prevented. There is a dearth of information on how to effectively prevent infections with human herpesvirus 6, Epstein-Barr virus, adenovirus, and BK virus.

According to earlier studies, the usage of some hair products, such as relaxers and pressing products, may raise the risk of ovarian cancer. The usage of hair straighteners may now also be related to uterine cancer, according to a recent study. The CDC lists using birth control pills, working out frequently, maintaining a healthy weight, and taking progesterone as required as factors that lower the risk of uterine cancer.

By capitalizing dissimilar letters, tall man writing helps distinguish between distinctive letter characters of similar medicine names that may be mistaken for one another. Since 2008, the ISMP has kept a list of medicine names in uppercase and bolded tall man letters. The organization surveyed 298 healthcare professionals between October and December 2022 to assist in updating the list, and the findings showed that tall man letters were frequently used: 74% of respondents consistently utilize tall man letters for organization-defined drug names in all necessary circumstances, and 80% of respondents said their facility employs tall man letters in all settings and across multiple facilities.

The approval was based on results from a 24-week open-label, two-part phase 3 trial that assessed Trikafta’s effectiveness and safety in 75 CF patients having at least one F508del mutation or a mutation known to be responsive to Trikafta. According to the findings, patients’ sweat chloride concentration and lung clearance index decreased in a clinically significant way. Trikafta therapy was typically well tolerated and commensurate with results seen in individuals who were older.